Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

31.33USD
12:20pm EDT
Change (% chg)

$-0.90 (-2.79%)
Prev Close
$32.23
Open
$32.07
Day's High
$32.58
Day's Low
$31.18
Volume
44,596
Avg. Vol
278,377
52-wk High
$41.75
52-wk Low
$15.97

Latest Key Developments (Source: Significant Developments)

Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment
Wednesday, 10 Jan 2018 08:00am EST 

Jan 10 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​.AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​.AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​.  Full Article

Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018.Aimmune Therapeutics Inc - ‍CEO Stephen Dilly plans to retire by end of 2018​.Aimmune Therapeutics Inc - ‍Aimmune will initiate a search for a successor CEO​.Aimmune Therapeutics Inc - ‍Dilly will continue as Aimmune's CEO until his replacement joins company and will be available through a transition period​.Aimmune Therapeutics Inc qtrly ‍on a per share basis, net loss for quarter was $0.63​.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Aimmune Therapeutics Inc - ‍expects last double-blind, placebo-controlled food challenge in phase 3 palisade trial of ar101 will be conducted in Dec. 2017​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments were $212.0 million at Sept 30, 2017, compared to $282.5 million at december 31, 2016​.Aimmune Therapeutics Inc - ‍top-line data from phase 3 palisade trial of ar101 will be available in q1 of 2018​.  Full Article

Aimmune Therapeutics files for mixed shelf of up to $250.0 mln - sec filing
Friday, 2 Sep 2016 04:53pm EDT 

Aimmune Therapeutics Inc :Files for mixed shelf of up to $250.0 million - sec filing.  Full Article

Aimmune Therapeutics says reaffirming its 2016 financial guidance
Wednesday, 10 Aug 2016 04:35pm EDT 

Aimmune Therapeutics Inc : Aimmune Therapeutics announces second quarter 2016 financial results . Says reaffirming its 2016 financial guidance . Qtrly loss per share $0.43 .Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Aimmune Therapeutics reports Q1 loss of $0.37 per share
Monday, 16 May 2016 04:05pm EDT 

Aimmune Therapeutics Inc : Aimmune is reaffirming its 2016 financial guidance . Fy2016 earnings per share view $-1.68, revenue view $0.00 -- Thomson Reuters I/B/E/S . Aimmune therapeutics announces first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.37 .Q1 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Aimmune Therapeutics Qtrly Loss Per Share $0.81

* AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS